Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
Abciximab (c7E3) is the Fab fragment of the chimeric (murine/human) monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor, which is the final common pathway for platelet aggregation. Abciximab has been widely used for patients undergoing angioplasty who are at high risk for ischemic complications. Severe thrombocytopenia (defined as platelet count < 50,000 platelet/mm3) has been observed in both first-time administration and re-administration of abciximab. Platelet transfusion as treatment for the reversal of thrombocytopenia is ubiquitously accepted. Intravenous corticosteroid as an adjunctive therapy is being explored. We previously reported our experience with platelet transfusion combined with corticosteroid treatment for acute thrombocytopenia following first-time abciximab administration. We now report a case of acute profound thrombocytopenia following re-administration of abciximab successfully treated with a combination of platelet transfusion and intravenous corticosteroid.
Published In/Presented At
Nguyen, N., Salib, H., & Mascarenhas, D. A. (2001). Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab. The Journal of invasive cardiology, 13(1), 56–58.
Medicine and Health Sciences
Department of Medicine